Comparison of the Immunogenicity and Safety of Three Enhanced Inactivated Poliovirus Vaccines from Different Manufacturers in Healthy Korean Infants: A Prospective Multicenter Study
Open Access
Abstract
The enhanced inactivated poliovirus vaccine was first introduced in 2002, and several inactivated poliovirus vaccines are licensed in Korea. Reliable data by a prospective study on the immunogenicity and safety of the inactivated poliovirus vaccines in Korean infants are required. Normal healthy infants aged 6–12 weeks received three doses of the vaccine (IPVAX™, Imovax Polio™ or Poliorix™) in intervals of 2 months. Neutralizing antibody (NTAb) titers were measured before and 4–6 weeks after three-dose primary vaccination. Immunogenicity was evaluated by seroconversion rates and geometric mean titers obtained by analyzing NTAb titers. Local and systemic adverse events were recorded during 7 days after each vaccination. A total of 150 infants were included: 40 in IPVAX™, 52 in Imovax Polio™, and 58 in Poliorix™. The seroconversion rates for the group vaccinated with IPVAX™ were 100% in types 1, 2 and 3, while those of Imovax Polio™ were 98.1%, 96.2%, 96.2% and those of Poliorix™ were 98.3%, 100%, 100%, respectively. In all groups, injection site redness and irritability were the most common local and systemic adverse events. Neither serious adverse events nor adverse events above grade 2 were reported throughout the study. The currently used inactivated poliovirus vaccines was demonstrated to be safe and immunogenic in healthy Korean infants.Keywords
Funding Information
- Ministry of Food and Drug Safety (09112MFDS427)
This publication has 15 references indexed in Scilit:
- Polio vaccines: WHO position paper – March, 2016.2016
- Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in ChinaVaccine, 2016
- Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority studyThe Lancet Infectious Diseases, 2015
- Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infantsVaccine, 2015
- Randomized Trial of Inactivated and Live Polio Vaccine Schedules in Guatemalan InfantsThe Journal of Infectious Diseases, 2007
- Serologic Response to Inactivated Poliovirus Vaccine: A Randomized Clinical Trial Comparing 2 Vaccination Schedules in Puerto RicoThe Journal of Infectious Diseases, 2007
- Immunogenicity and safety of enhanced-inactivated poliovaccine(eIPV) in healthy Korean infantsKorean Journal of Pediatrics, 2006
- Comparative Evaluation of Immunization with Live Attenuated and Enhanced-Potency Inactivated Trivalent Poliovirus Vaccines in Childhood: Systemic and Local Immune ResponsesThe Journal of Infectious Diseases, 1990
- CLINICAL EFFICACY OF A NEW, ENHANCED-POTENCY, INACTIVATED POLIOVIRUS VACCINEThe Lancet, 1988
- Antibody Response of Infants to Two Doses of Inactivated Poliovirus Vaccine of Enhanced PotencyArchives of Pediatrics & Adolescent Medicine, 1985